XASX
LDX
Market cap56mUSD
, Last price
AUD
Name
Lumos Diagnostics Holdings Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
47.05%
Rev. 5Y
-6.49%
Div Yld LY
—
Div Yld TTM
—
Revenues
13m
+7.85%
Net income
-5m
L-29.55%
CFO
1m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
Key people
Samuel Lanyon
Executive Chairman of the Board · since 2022
Barrie Lambert
Chief Financial Officer · since 2022
Paul Kase
Senior Vice President of Commercial Operations
Sacha Dopheide
Chief Technology Officer
Kepa Oyarbide
Vice President Technology Transfer and Pilot Manufacturing
Doug Ward
Chief Executive Officer, Managing Director, Director · since 2023
Annie Bell
Senior Director of Medical Affairs
Sarah Glubka
Senior Director of Human Resources
Sue Hibbeln
Senior Director of Regulatory Affairs
Company Secretary · since 2022
Tracy Weimar
Company Secretary
Lawrence Mehren
Non-Executive Deputy Chairman of the Board · since 2020
Non-Executive Director · since 2020
Non-Executive Director · since 2020
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||